Compounds > chlorthalidone
Page last updated: 2024-10-25

chlorthalidone and Insulin Resistance

chlorthalidone has been researched along with Insulin Resistance in 4 studies

Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.

Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.

Research Excerpts

ExcerptRelevanceReference
"Recent studies from our laboratory indicate that chlorthalidone triggers persistent activation of the sympathetic nervous system and promotes insulin resistance in hypertensive patients, independent of serum potassium."9.16Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. ( Adams-Huet, B; Arbique, D; Auchus, RJ; Price, A; Raheja, P; Vongpatanasin, W; Wang, Z, 2012)
"Recent studies from our laboratory indicate that chlorthalidone triggers persistent activation of the sympathetic nervous system and promotes insulin resistance in hypertensive patients, independent of serum potassium."5.16Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. ( Adams-Huet, B; Arbique, D; Auchus, RJ; Price, A; Raheja, P; Vongpatanasin, W; Wang, Z, 2012)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Castro-Torres, Y1
Fleites-Pérez, A1
Carmona-Puerta, R1
Jiménez-Garrido, RG1
Leenen, FH1
Ruzicka, M1
Floras, JS1
Raheja, P1
Price, A1
Wang, Z1
Arbique, D1
Adams-Huet, B1
Auchus, RJ1
Vongpatanasin, W1
Kapoor, S1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Neural Mechanisms of Thiazide-induced Insulin Resistance[NCT00353652]Phase 4166 participants (Actual)Interventional2005-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

24-hour Ambulatory Systolic Blood Pressure

(NCT00353652)
Timeframe: Measured at 3 months

InterventionmmHg (Mean)
Study#1: Chlorthalidone (CTD), Titrated Dose127.4
Study #1: Spironolactone (SP), Titrated Dose128.6
Study# 2 Chlorthalidone (CTD), Fixed Dose123.5
Study# 2 CTD Fixed Dose 25 mg/d Plus SP Fixed Dose121.6
Study# 2 CTD Fixed Dose 25 mg/d Plus IR Fixed Dose119.8

HOMA-IR

assessment of insulin resistance calculated by multiplying fasting plasma insulin (mU/l) with fasting plasma glucose (mmol/l) divided by 22.5. (NCT00353652)
Timeframe: 3 months

InterventionmU/l*mmol/l (Median)
Study#1: Chlorthalidone (CTD), Titrated Dose1.91
Study #1: Spironolactone (SP), Titrated Dose1.33
Study# 2 Chlorthalidone (CTD), Fixed Dose1.87
Study# 2 CTD Fixed Dose 25 mg/d Plus SP Fixed Dose0.85
Study# 2 CTD Fixed Dose 25 mg/d Plus IR Fixed Dose1.42

Insulin

fasting plasma insulin (NCT00353652)
Timeframe: 3 months

InterventionmU/liter (Median)
Study#1: Chlorthalidone (CTD), Titrated Dose8.24
Study #1: Spironolactone (SP), Titrated Dose7.6
Study# 2 CTD Fixed Dose 25 mg/d7.6
Study# 2 CTD Fixed Dose 25 mg/d Plus SP Fixed Dose4.87
Study# 2 CTD Fixed Dose 25 mg/d Plus IR Fixed Dose6.8

Sympathetic Baroreflex Sensitivity

slope relating percent change in SNA (% change in total activity from baseline) to diastolic BP. (NCT00353652)
Timeframe: 3 months

Intervention% change from baseline per mmHg (Mean)
Study#1: Chlorthalidone (CTD), Titrated Dose-9.1
Drug: Study #1: Spironolactone (SP), Titrated Dose-15.2
Study# 2 Chlorthalidone (CTD), Fixed Dose-12.9
Study# 2 CTD Fixed Dose 25 mg/d Plus SP Fixed Dose-11.3
Study# 2 CTD Fixed Dose 25 mg/d Plus IR Fixed Dose-12.0

Sympathetic Nerve Activity

(NCT00353652)
Timeframe: Measured at 3 months

Interventionbursts/min (Mean)
Study#1: Chlorthalidone (CTD), Titrated Dose46
Study #1: Spironolactone (SP), Titrated Dose40
Study# 2 Chlorthalidone (CTD), Fixed Dose49
Study# 2 CTD Fixed Dose 25 mg/d Plus SP Fixed Dose42
Study# 2 CTD Fixed Dose 25 mg/d Plus IR Fixed Dose52

Reviews

1 review available for chlorthalidone and Insulin Resistance

ArticleYear
Negative effects of chlorthalidone on sympathetic nervous system and insulin resistance in hypertensive patients may be avoided with spironolactone: further studies are still needed.
    Irish journal of medical science, 2015, Volume: 184, Issue:4

    Topics: Blood Pressure; Chlorthalidone; Humans; Hypertension; Insulin Resistance; Spironolactone; Sympatheti

2015

Trials

1 trial available for chlorthalidone and Insulin Resistance

ArticleYear
Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients.
    Hypertension (Dallas, Tex. : 1979), 2012, Volume: 60, Issue:2

    Topics: Action Potentials; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Chlorthalidone; Cros

2012

Other Studies

2 other studies available for chlorthalidone and Insulin Resistance

ArticleYear
Central sympathetic inhibition by mineralocorticoid receptor but not angiotensin II type 1 receptor blockade: are prescribed doses too low?
    Hypertension (Dallas, Tex. : 1979), 2012, Volume: 60, Issue:2

    Topics: Chlorthalidone; Female; Humans; Hypertension; Insulin Resistance; Male; Spironolactone; Sympathetic

2012
Emerging pain ameliorating effects of spironolactone: an additional benefit of its use in hypertensive and cardiac patients: recent insights.
    Hypertension (Dallas, Tex. : 1979), 2012, Volume: 60, Issue:6

    Topics: Chlorthalidone; Female; Humans; Hypertension; Insulin Resistance; Male; Spironolactone; Sympathetic

2012